Lisata Therapeutics Inc (LSTA)

[Viperciara]

Dr. David J. Mazzo, NeoStem’s Chief Executive Officer. “The grant substantiates our approach to identifying and securing non-dilutive funding for our development programs and helps position NeoStem as a leader among immuno-oncology therapy developers.” - See more at: http://www.neostem.com/media/press-releases/news-item/major-grant-advances-pioneering-melanoma-therapy-at-neostem/#sthash.mW5TgI9x.dpuf

I guess he did not actually mean this??? He told us this on may21st 2015!

New York, May 27, 2015 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today that it is commencing an underwritten public offering of its common stock. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Why does it say they need it especially in NBS20??? That is where the grant is for???